Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Switching HIV regimens from a daily oral pill to a monthly injectable has given Alex Vance more headspace.
Injectable cabotegravir and rilpivirine are approved for people with viral suppression who would prefer monthly injections to daily pills.
I just attended my first CROI (Conference on Retroviruses and Opportunistic Infections). It was also my first virtual conference...
The week of March 6 – March 10, 2021 I had the privilege of attending the Conference on Retroviruses and Opportunistic Infections (CROI).
A study finds that long-acting cabotegravir is an effective PrEP option for women.
Cabotegravir injections and daily Truvada are both highly effective, but some people may find it easier to use the long-acting regimen.
Whether for treatment or prevention, women’s interest in injectable antiretrovirals varied based on their relationship with injection.
A clinical trial found that switching HIV meds to long-acting Cabenuva may not require oral lead-in.
COVID-19, HIV vaccines, cure news and long-acting injectables stood out among the top HIV treatment stories of the year.
The European Medicines Agency gave the green light to injectable cabotegravir and rilpivirine for HIV treatment.
A study analyzed how well people with HIV and their health care providers can navigate the experimental long-acting injectable Cabenuva.
Long-acting injectable cabotegravir for HIV prevention could hit the market for men and women in early 2022.
After years of taking daily oral cabotegravir and Edurant, people with suppressed HIV switched to long-acting injectable Cabenuva.
A study found no difference in outcomes based on whether participants took oral meds for a month before switching to injectables.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.